Earning Analysis
Welcome to our in-depth analysis of Bausch Health Companies Inc(BHC) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Bausch Health Companies Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2025Q3 | 2025-10-29 | After Hours | 1.07 | 1.16 | +8.41 | 2.63B | 2.68B | +2.11 | +12.03 | +14.24 |
| FY2025Q2 | 2025-07-30 | After Hours | 0.97 | 0.40 | -58.76 | 2.49B | 2.53B | +1.79 | -7.82 | -7.04 |
| FY2025Q1 | 2025-04-30 | After Hours | 0.83 | 0.68 | -17.58 | 2.28B | 2.26B | -0.77 | - | -11.32 |
| FY2024Q4 | 2025-02-19 | After Hours | 1.12 | 1.21 | +8.04 | 2.51B | 2.56B | +1.75 | +10.29 | +18.28 |
| FY2024Q3 | 2024-10-30 | After Hours | 1.03 | -0.23 | -122.33 | 2.42B | 2.51B | +3.63 | +12.61 | +16.28 |
| FY2024Q2 | 2024-08-01 | - | 0.89 | 0.89 | - | 2.34B | 2.40B | +2.79 | +1.16 | -13.43 |
| FY2024Q1 | 2024-05-02 | - | 0.75 | 0.59 | -21.33 | 2.16B | 2.15B | -0.44 | -7.54 | -19.66 |
| FY2023Q4 | 2024-02-22 | - | 1.01 | 1.15 | +13.86 | 2.29B | 2.41B | +4.93 | +7.27 | +6.11 |
| FY2023Q3 | 2023-11-02 | - | 0.92 | 1.03 | +11.96 | 2.16B | 2.24B | +3.72 | +3.67 | +1.27 |
| FY2023Q2 | 2023-08-03 | - | 0.75 | 0.81 | +8.00 | 2.05B | 2.17B | +5.86 | +0.86 | -7.61 |
BHC Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Bausch Health Companies Inc reported performance for FY2025Q3, announced on 2025-10-29. The company achieved an EPS of 1.16, compared to analyst estimates of 1.07 by 8.41% . Revenue for the quarter reached 2.68B compared to expectations of 2.63B by 2.11% .
The stock price reacted with a 12.03% one-day change and a 14.24% five-day change following the earnings release. These movements reflect market reaction in Bausch Health Companies Inc growth trajectory and strategic initiatives.
BHC Earnings Forecast
Looking ahead, Bausch Health Companies Inc(BHC) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 2.72B and an EPS of 1.25.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 0.91%, while EPS estimates have been Revise Upward by 6.51%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 0.41% . These revisions correlate with a 0.41% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Bausch Health Companies Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between BHC's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
+0.91%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+6.51%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Upward
+0.41%
In Past 3 Month
Stock Price
Go Up
+0.41%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:10.19B
--
EPS Estimate-Annual FY 2025:3.89
—
Stock Price7.38
BHC Revenue and EPS Performance: A Historical Perspective
Bausch Health Companies Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-10-29,After Hours):
EPS: 1.16 (Actual) vs.1.07 (Estimate) (8.41%)
Revenue: 2.68B (Actual) vs. 2.63B (Estimate) (2.11%)
Price Reaction: 12.03%(1-Day), 14.24%(5-Day)
FY2025Q2 (2025-07-30,After Hours):
EPS: 0.40 (Actual) vs.0.97 (Estimate) (-58.76%)
Revenue: 2.53B (Actual) vs. 2.49B (Estimate) (1.79%)
Price Reaction: -7.82%(1-Day), -7.04%(5-Day)
FY2025Q1 (2025-04-30,After Hours):
EPS: 0.68 (Actual) vs.0.83 (Estimate) (-17.58%)
Revenue: 2.26B (Actual) vs. 2.28B (Estimate) (-0.77%)
Price Reaction: 0.00%(1-Day), -11.32%(5-Day)
Earnings Reaction
The chart below shows how BHC performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BHC sees a +1.97% change in stock price 10 days leading up to the earnings, and a -0.80% change 10 days following the report. On the earnings day itself, the stock moves by -0.69%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 12.03% on the day following the earnings release and then changed by 17.63% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Bausch Health Companies Inc (BHC) Q3 2025 Earnings Call Summary
Positive
2025-10-29
The earnings call indicates strong growth in Bausch + Lomb and international segments, and strategic initiatives like debt refinancing and acquisitions bolster long-term prospects. Despite some revenue declines and conservative guidance adjustments, positive Q&A insights on Xifaxan's growth and RED-C trials suggest optimism. Market reaction should be positive, with a projected 2-8% stock price increase, considering the company's market cap and strategic positioning.
Bausch Health Companies Inc (BHC) Q2 2025 Earnings Call Summary
Positive
2025-07-30
The earnings call presents a mix of positive and neutral factors. Strong financial performance, including revenue and EBITDA growth, and positive developments in product segments like Salix and Solta Medical, contribute to a positive outlook. However, concerns over the IRA impact on Xifaxan and limited details on the DURECT acquisition introduce some uncertainty. The shift away from share buybacks could be seen as a negative, but overall, the positive financial metrics and strategic focus on growth suggest a positive stock movement in the short term.
Bausch Health Companies Inc (BHC) Q1 2025 Earnings Call Summary
Neutral
2025-04-30
The earnings call presents mixed signals: financial results show modest revenue growth and debt reduction, but margins have declined and refinancing increased costs. The guidance is optimistic, yet management's vague responses in Q&A raise concerns. The market cap suggests a moderate reaction. Overall, the sentiment is neutral, with no strong catalysts to drive significant stock price movement.
Bausch Health Companies Inc (BHC) Q4 2024 Earnings Call Summary
Positive
2025-02-20
Despite missing EPS expectations, Bausch Health showed strong financial performance with increased revenue, adjusted EBITDA, and cash flow. The raised guidance for 2024 and significant debt reduction are positive indicators. While the Norwich case presents some risk, management's focus on operational excellence and shareholder value, along with the potential for capital market tapping, supports a positive outlook. Given the market cap, a 2% to 8% stock price increase is likely.
Bausch Health Companies, Inc. (BHC) Q3 2024 Earnings Call Summary
Positive
2024-10-31
The earnings call summary shows strong financial performance with a 12% revenue increase and a 10% rise in adjusted EBITDA. The company also raised its cash flow guidance, indicating optimism. However, there are concerns about legal disputes and management's unclear responses in the Q&A. Despite this, the strong financial metrics and guidance raise suggest a positive market reaction, supported by the market cap indicating a moderate response.
Bausch Health Companies (BHC) Q2 2024 Earnings Call Summary
Neutral
2024-08-01
The earnings call presented a mix of positive and negative factors. Financial performance showed growth in revenue and EBITDA, but concerns about debt and liquidity remain. The Q&A section highlighted management's avoidance of clear answers on leverage and separation strategy, adding uncertainty. Despite strong revenue growth, the lack of updated guidance and ongoing debt issues suggest a neutral impact on stock price, especially given the mid-sized market cap of approximately $2.5 billion, which may temper volatility.
People Also Watch
FAQ
What were the key highlights of BHC’s latest earnings report for FY2025Q3?
How did BHC’s stock price react after the FY2025Q3 earnings release?
What are the revenue and EPS estimates for BHC for 2025/Q4?
How does BHC’s stock price correlate with earnings forecast revisions?
What should investors expect from BHC’s next earnings report?